WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "03103992-fe68-4156-ac53-0cfc76f3c4d0"}, "_deposit": {"created_by": 18, "id": "45331", "owners": [18], "pid": {"revision_id": 0, "type": "depid", "value": "45331"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00045331", "sets": ["2817"]}, "author_link": ["78827", "78826"], "item_9_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-06-14", "bibliographicIssueDateType": "Issued"}, "bibliographicPageStart": "4p.", "bibliographicVolumeNumber": "2014-04-01 - 2017-03-31", "bibliographic_titles": [{"bibliographic_title": "平成28(2016)年度 科学研究費補助金 基盤研究(C) 研究成果報告書"}, {"bibliographic_title": "2016 Fiscal Year Final Research Report", "bibliographic_titleLang": "en"}]}]}, "item_9_creator_33": {"attribute_name": "著者別表示", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Sone, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "78827", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30420334", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=30420334"}]}]}, "item_9_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "EGFR遺伝子変異陰性の進行再発非小細胞肺癌に対するエルロチニブの有効性安全性の第II相試験に登録された患者の腫瘍を用いて、エルロチニブの効果予測因子となる遺伝子異常を検討した。c-Metの遺伝子増幅は56例で解析可能であり、c-Met遺伝子増幅陰性症例でエルロチニブの無増悪生存期間が長い傾向を認めた。主要な遺伝子変異15を含むパネルを用いた次世代シークエンスを17例で実施し、TP53遺伝子変異を10例で認めたがエルロチニブの効果と関連は認めなかった。本解析では多くの遺伝子変異解析でlow coverageをで認め腫瘍のDNAの質の低下が問題となり次世代シークエンスの結果に影響をもたらした。", "subitem_description_type": "Abstract"}, {"subitem_description": "We analyzed predictive biomarker of erlotinib to NSCLC patients(pts) who have wild-type EGFR.We utilized tumor tissue from the phase II study to evaluate of erlotinib in advanced NSCLC pts who have wild-type EGFR. C-Met gene amplification (GA) was evaluable in 56 patients and 11 pts showed c-Met GA. Progression free survivals of erlotinib was longer in pts with c-Met GA than those without GA. Next-gene-sequence (NGS) was analyzed in 17 pts using cancer panel of fifteen oncogene (TruSight Tumor 15). TP53 mutation was detected 10 pts among 17 pts. There was no difference in DCR, PFS between pts with TP53 mutation and those without TP53 mutation. In NGS analysis, \"low coverage\" was frequently observed due to low amount and low quality of DNA.\nIn our study, we could\u0027nt detect biomarker of efficacy of erlotinib to EGFR-wild pts.In NGS analysis using tinny tissue collected for diagnosis, it is matter to keep quality of DNA.", "subitem_description_type": "Abstract"}]}, "item_9_description_22": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "研究課題/領域番号:26430161, 研究期間(年度):2014-04-01 - 2017-03-31", "subitem_description_type": "Other"}, {"subitem_description": "出典:「EGFR遺伝子変異陰性肺癌におけるエルロチニブの効果予測因子の検討」研究成果報告書 課題番号26430161\n(KAKEN:科学研究費助成事業データベース(国立情報学研究所))\n(https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26430161/26430161seika/)を加工して作成", "subitem_description_type": "Other"}]}, "item_9_description_5": {"attribute_name": "提供者所属", "attribute_value_mlt": [{"subitem_description": "金沢大学医薬保健学総合研究科", "subitem_description_type": "Other"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.24517/00051668", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_relation_28": {"attribute_name": "関連URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "https://kaken.nii.ac.jp/search/?qm=30420334"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://kaken.nii.ac.jp/search/?qm=30420334", "subitem_relation_type_select": "URI"}}, {"subitem_relation_name": [{"subitem_relation_name_text": "https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26430161/"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26430161/", "subitem_relation_type_select": "URI"}}, {"subitem_relation_name": [{"subitem_relation_name_text": "https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26430161/26430161seika/"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26430161/26430161seika/", "subitem_relation_type_select": "URI"}}]}, "item_9_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "曽根, 崇"}], "nameIdentifiers": [{"nameIdentifier": "78826", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30420334", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=30420334"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-07-13"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ME-PR-SONE-T-kaken 2017-4p.pdf", "filesize": [{"value": "95.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_11", "mimetype": "application/pdf", "size": 95100.0, "url": {"label": "ME-PR-SONE-T-kaken 2017-4p.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/45331/files/ME-PR-SONE-T-kaken 2017-4p.pdf"}, "version_id": "e3c47be6-1d75-4346-8291-be9335c8f60d"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "EGFR遺伝子変異陰性", "subitem_subject_scheme": "Other"}, {"subitem_subject": "エルロチニブ", "subitem_subject_scheme": "Other"}, {"subitem_subject": "次世代シークエンス", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "research report", "resourceuri": "http://purl.org/coar/resource_type/c_18ws"}]}, "item_title": "EGFR遺伝子変異陰性肺癌におけるエルロチニブの効果予測因子の検討", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "EGFR遺伝子変異陰性肺癌におけるエルロチニブの効果予測因子の検討"}, {"subitem_title": "Analysis of predictive biomarker of Erlotinib to non-small cell lung cancer without EGFR mutation", "subitem_title_language": "en"}]}, "item_type_id": "9", "owner": "18", "path": ["2817"], "permalink_uri": "https://doi.org/10.24517/00051668", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-07-13"}, "publish_date": "2018-07-13", "publish_status": "0", "recid": "45331", "relation": {}, "relation_version_is_last": true, "title": ["EGFR遺伝子変異陰性肺癌におけるエルロチニブの効果予測因子の検討"], "weko_shared_id": -1}
EGFR遺伝子変異陰性肺癌におけるエルロチニブの効果予測因子の検討
https://doi.org/10.24517/00051668
https://doi.org/10.24517/000516684d208356-730b-453a-be30-0655be48cbf2
名前 / ファイル | ライセンス | アクション |
---|---|---|
ME-PR-SONE-T-kaken 2017-4p.pdf (95.1 kB)
|
Item type | 報告書 / Research Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-07-13 | |||||
タイトル | ||||||
タイトル | EGFR遺伝子変異陰性肺癌におけるエルロチニブの効果予測因子の検討 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Analysis of predictive biomarker of Erlotinib to non-small cell lung cancer without EGFR mutation | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_18ws | |||||
資源タイプ | research report | |||||
ID登録 | ||||||
ID登録 | 10.24517/00051668 | |||||
ID登録タイプ | JaLC | |||||
著者別表示 |
Sone, Takashi
× Sone, Takashi |
|||||
提供者所属 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 金沢大学医薬保健学総合研究科 | |||||
書誌情報 |
平成28(2016)年度 科学研究費補助金 基盤研究(C) 研究成果報告書 en : 2016 Fiscal Year Final Research Report 巻 2014-04-01 - 2017-03-31, p. 4p., 発行日 2017-06-14 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | EGFR遺伝子変異陰性の進行再発非小細胞肺癌に対するエルロチニブの有効性安全性の第II相試験に登録された患者の腫瘍を用いて、エルロチニブの効果予測因子となる遺伝子異常を検討した。c-Metの遺伝子増幅は56例で解析可能であり、c-Met遺伝子増幅陰性症例でエルロチニブの無増悪生存期間が長い傾向を認めた。主要な遺伝子変異15を含むパネルを用いた次世代シークエンスを17例で実施し、TP53遺伝子変異を10例で認めたがエルロチニブの効果と関連は認めなかった。本解析では多くの遺伝子変異解析でlow coverageをで認め腫瘍のDNAの質の低下が問題となり次世代シークエンスの結果に影響をもたらした。 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | We analyzed predictive biomarker of erlotinib to NSCLC patients(pts) who have wild-type EGFR.We utilized tumor tissue from the phase II study to evaluate of erlotinib in advanced NSCLC pts who have wild-type EGFR. C-Met gene amplification (GA) was evaluable in 56 patients and 11 pts showed c-Met GA. Progression free survivals of erlotinib was longer in pts with c-Met GA than those without GA. Next-gene-sequence (NGS) was analyzed in 17 pts using cancer panel of fifteen oncogene (TruSight Tumor 15). TP53 mutation was detected 10 pts among 17 pts. There was no difference in DCR, PFS between pts with TP53 mutation and those without TP53 mutation. In NGS analysis, "low coverage" was frequently observed due to low amount and low quality of DNA. In our study, we could'nt detect biomarker of efficacy of erlotinib to EGFR-wild pts.In NGS analysis using tinny tissue collected for diagnosis, it is matter to keep quality of DNA. |
|||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 研究課題/領域番号:26430161, 研究期間(年度):2014-04-01 - 2017-03-31 | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 出典:「EGFR遺伝子変異陰性肺癌におけるエルロチニブの効果予測因子の検討」研究成果報告書 課題番号26430161 (KAKEN:科学研究費助成事業データベース(国立情報学研究所)) (https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26430161/26430161seika/)を加工して作成 |
|||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://kaken.nii.ac.jp/search/?qm=30420334 | |||||
関連名称 | https://kaken.nii.ac.jp/search/?qm=30420334 | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26430161/ | |||||
関連名称 | https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26430161/ | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26430161/26430161seika/ | |||||
関連名称 | https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26430161/26430161seika/ |